Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 21, 2024; 30(43): 4609-4619
Published online Nov 21, 2024. doi: 10.3748/wjg.v30.i43.4609
Published online Nov 21, 2024. doi: 10.3748/wjg.v30.i43.4609
Plasma DNA methylation detection for early screening, diagnosis, and monitoring of esophageal adenocarcinoma and squamous cell carcinoma
Xu-Ji Liu, Hui Zeng, Department of Radiotherapy and Oncology, Wuhan Sixth Hospital and Affiliated Hospital of Jianghan University, Wuhan 430015, Hubei Province, China
Xu-Ji Liu, Department of Radiotherapy and Oncology, Jianghan University, School of Medicine, Wuhan 430015, Hubei Province, China
Guo-Liang Pi, Hong-Wei Shi, Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430079, Hubei Province, China
Sheng Wang, Jin-Dan Kai, Hui-Fang Yu, Department of Thoracic Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430079, Hubei Province, China
Jing Yu, Department of Laboratory Medicine, Wuhan Hospital of Traditional Chinese and Western Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China
Co-first authors: Xu-Ji Liu and Guo-Liang Pi.
Co-corresponding authors: Jing Yu and Hui Zeng.
Author contributions: Yu J, Liu XJ, and Pi GL had access to all the clinical data generated by the study and take responsibility for data integrity and accuracy of the data analysis; Yu J and Zeng H contributed to study concept and design; Wang S, Kai JD, Yu HF, and Shi HW contributed to acquisition, analysis, or interpretation of the data; Yu J and Liu XJ contributed to manuscript preparation.
Supported by The Medical Talents of Wuhan Hospital of Traditional Chinese and Western Medicine , No. 202212001 ; Hubei Natural Science Foundation , No. 2023AFB1091 and No. 2023AFB988 ; The 7th Wuhan Young and Middle-Aged Backbone Talent of Medical Training Project; No. 2019-87; and The Research Projects of Biomedical Center of Hubei Cancer Hospital , No. 2022SWZX19 .
Institutional review board statement: The study was conducted according to the Declaration of Helsinki and approved by the ethics committee at Hubei Cancer Hospital (No. LLHBCH2023YN-004).
Informed consent statement: Patient consent was waived due to the retrospective study design by the ethics committee at Hubei Cancer hospital.
Conflict-of-interest statement: The authors declare no conflict of interest for this article.
Data sharing statement: We could provide raw data if it is necessary.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jing Yu, PhD, Doctor, Department of Laboratory Medicine, Wuhan Hospital of Traditional Chinese and Western Medicine, Tongji Medical College, Huazhong University of Science and Technology, No. 215 Zhongshan Road, Wuhan 430022, Hubei Province, China. yujings9774@sina.com.cn
Received: June 10, 2024
Revised: September 6, 2024
Accepted: September 13, 2024
Published online: November 21, 2024
Processing time: 142 Days and 22.1 Hours
Revised: September 6, 2024
Accepted: September 13, 2024
Published online: November 21, 2024
Processing time: 142 Days and 22.1 Hours
Core Tip
Core Tip: This study for the first time analyzed the clinical value of detecting plasma SHOX2, SEPTIN9, EPO, and RNF180 methylation for diagnosis and monitoring of esophageal cancer (EC). We revealed that the sensitivity and specificity of combined assessment of methylation of the four genes in plasma for detecting EC were 76.19% and 86.27%, respectively; the area under the curve value of this combination was 0.864 (95% confidence interval: 0.809–0.92). The accurate measurement of methylation of these four genes in plasma might aid monitoring of therapy efficacy in both esophageal adenocarcinoma and squamous cell carcinoma.